The present disclosure relates to a pharmaceutical composition comprising a nucleic acid molecule of an adjuvant, a metal complex stabilizing the nucleic acid molecule, and optionally an immunogen that may be a peptide or a protein, or a composition of stabilizing the nucleic acid molecule of the adjuvant comprising the metal complex. The metal complex interacts with the nucleic acid molecule of the adjuvant and/or the immunogen so as to stabilize such pharmaceutically active ingredients, and induces continuous effectiveness of the active ingredients without degradation.

According to one embodiment, a reporter vector includes a first and a second reporter gene expression unit and a replication initiation sequence. The first reporter gene expression unit includes a promoter sequence of a cell characteristics marker, a first reporter gene, and a first transcription termination sequence. The second reporter gene expression unit includes a promoter sequence exhibiting constitutive activity, a second reporter gene, a bicistronic expression sequence, a replication initiation protein gene, and a second transcription termination sequence. The replication initiation sequence binds to a replication initiation protein, thereby initiating replication of the reporter vector.

The present disclosure relates to a pharmaceutical composition comprising a nucleic acid molecule of an adjuvant, a metal complex stabilizing the nucleic acid molecule, and optionally an immunogen that may be a peptide or a protein, or a composition of stabilizing the nucleic acid molecule of the adjuvant comprising the metal complex. The metal complex interacts with the nucleic acid molecule of the adjuvant and/or the immunogen so as to stabilize such pharmaceutically active ingredients, and induces continuous effectiveness of the active ingredients without degradation.